Publication | Open Access

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Lymphoid NeoplasiaPinatuzumab VedotinMedicinePolatuzumab VedotinMalignant Blood DisorderImmunologyRefractory Non-hodgkin LymphomaPathologyImmunotherapyOncologyRadiation OncologyCancer Research